Drug Profile
Pegloxenatide - Jiangsu Hengrui Medicine Co.
Alternative Names: PEG loxenatide; PEX-168; Polyethylene glycol loxenatideLatest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Developer Jiangsu Hansoh Pharmaceutical; Jiangsu Hengrui Medicine Co.
- Class Antihyperglycaemics; Obesity therapies; Peptides; Polyethylene glycols
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Type 2 diabetes mellitus
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in China (SC, Injection)
- 20 Sep 2019 Jiangsu Hansoh Pharmaceutical completes a phase III trial in Type 2 diabetes mellitus in China (NCT02477969)
- 16 Sep 2019 Safety and efficacy data from a phase III trial in Type-2 diabetes mellitus presented at 55th Annual Meeting pf the European Association for the Study of Diabetes (EASD-2019)